On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Investigational product in the cited studies; trial participation is distinct from an approved treatment.
Two receptor systems
Survodutide targets glucagon and GLP-1 receptors. The balance of effects must be evaluated in human outcomes rather than inferred from receptor names. [1]
What the evidence shows
Obesity trial
A phase 2 trial randomized 387 adults without diabetes and studied treatment for 46 weeks. Weight reduction was greater with survodutide than placebo. [1]
Completion affects interpretation
About 60% of treated participants completed the treatment period. Analyses of assigned treatment and actual maintenance treatment answer different questions; a single headline percentage can hide those distinctions. [1]
What remains unknown
This obesity study does not establish long-term cardiovascular outcomes or justify extending results to every liver condition.
Safety
Gastrointestinal tolerance
Nausea and other gastrointestinal events were important adverse effects in the trial. A finding of weight loss is not evidence that escalating exposure is harmless. [1]
Research formulation
The cited trial administered a subcutaneous study product; results cannot establish equivalence of a differently supplied formulation. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [2]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [3]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
How is this different from a GLP-1-only medicine?
It also stimulates the glucagon receptor. That explains a research strategy, not a guarantee of better results.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial2024 · Primary research · PubMed
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.